Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 1:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Trigeminal Autonomic Cephalgia Clear all
Completed Phase 2Phase 3 Interventional Results available

Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches

NCT04066023
View directory record Official record
Conditions
Cluster Headache
Interventions
C213 Microneedle System, Placebo
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 10, 2026, 1:44 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Will Erwin Headache Research Center - Cluster Headache Study

NCT02910323
View directory record Official record
Conditions
Cluster Headache, Cluster Headaches and Other Trigeminal Autonomic Cephalgias, Paroxysmal Hemicrania, SUNCT, Hemicrania Continua, Trigeminal Neuralgia
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2035
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 10, 2026, 1:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Osteopathic Manual Therapy (OMT) and Brain Structure and Function in Primary Headache Patients: A Pilot Study

NCT06841627
View directory record Official record
Conditions
Primary Headaches (Migraines, Tension, Cluster Headaches)
Interventions
Osteopathic Manipulative Therapy
Other
Lead sponsor
Edward Via Virginia College of Osteopathic Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 10, 2026, 1:44 PM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

NCT04930887
View directory record Official record
Conditions
Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal Hemicrania
Interventions
Exparel (Bupivacaine Liposome), Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 10, 2026, 1:44 PM EDT
Terminated Phase 4 Interventional

A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache

NCT00203190
View directory record Official record
Conditions
Cluster Headache
Interventions
Topiramate
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2009 · Synced Sep 10, 2026, 1:44 PM EDT
Completed Phase 2 Interventional

Cluster Headache Treatment With Rimegepant

NCT05264714
View directory record Official record
Conditions
Cluster Headache
Interventions
Rimegepant
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 10, 2026, 1:44 PM EDT
Completed Phase 3 Interventional

Intranasal Civamide for Episodic Cluster Headache

NCT00069082
View directory record Official record
Conditions
Episodic Cluster Headache
Interventions
Civamide (Zucapsaicin), Sodium Chloride
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
6
States / cities
San Francisco, California • Santa Monica, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Sep 10, 2026, 1:44 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache

NCT03107052
View directory record Official record
Conditions
Cluster Headache
Interventions
Fremanezumab
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Phoenix, Arizona • Canoga Park, California • Santa Monica, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 10, 2026, 1:44 PM EDT
Terminated Not applicable Interventional

High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache

NCT04570475
View directory record Official record
Conditions
Cluster Headache
Interventions
Vitamin D, multivitamin, Placebo
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 10, 2026, 1:44 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 10, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

Eptinezumab in Participants With Episodic Cluster Headache

NCT04688775
View directory record Official record
Conditions
Cluster Headache, Episodic
Interventions
Eptinezumab, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 10, 2026, 1:44 PM EDT
Terminated Phase 1 Interventional Results available

A Pilot Study of Demand Valve Oxygen Inhalation Therapy for Cluster Headache

NCT01298921
View directory record Official record
Conditions
Cluster Headache
Interventions
Oxygen
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Sep 10, 2026, 1:44 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache

NCT02381795
View directory record Official record
Conditions
Cluster Headache
Interventions
Nasal Carbon Dioxide
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Sep 10, 2026, 1:44 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Quest to Analyze One Thousand Humans Meditating

NCT06583395
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions
Advanced multi-component meditation practice
Behavioral
Lead sponsor
Tobias Moeller-Bertram
Industry
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palm Desert, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 10, 2026, 1:44 PM EDT
Completed No phase listed Observational

Cluster Headache Treatment Survey

NCT06011811
View directory record Official record
Conditions
Cluster Headache
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
2,487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 10, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache

NCT02797951
View directory record Official record
Conditions
Episodic Cluster Headache, Chronic Cluster Headache
Interventions
Galcanezumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
11
States / cities
Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Sep 10, 2026, 1:44 PM EDT
Completed Not applicable Interventional Results available

An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches.

NCT00203242
View directory record Official record
Conditions
Cluster Headache
Interventions
Depacon IV and Depakote ER
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2011 · Synced Sep 10, 2026, 1:44 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

NCT02619617
View directory record Official record
Conditions
Cluster Headache - Episodic and Chronic
Interventions
SOM230, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Culver City, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 10, 2026, 1:44 PM EDT
Not listed Not applicable Interventional

Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache

NCT02168764
View directory record Official record
Conditions
Chronic Cluster Headache
Interventions
ATI Neurostimulation System
Device
Lead sponsor
Autonomic Technologies, Inc.
Industry
Eligibility
22 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 10, 2026, 1:44 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)

NCT02945046
View directory record Official record
Conditions
Episodic Cluster Headache
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Phoenix, Arizona • Canoga Park, California • Santa Monica, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 10, 2026, 1:44 PM EDT
Completed No phase listed Observational Results available

A Research Study to Examine Cutaneous Allodynia and Cluster Headache

NCT00329836
View directory record Official record
Conditions
Cluster Headache
Interventions
There are no interventions in the observational study. The symptom of allodynia was measured.
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 10, 2026, 1:44 PM EDT
Completed Phase 3 Interventional

A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache

NCT00033839
View directory record Official record
Conditions
Episodic Cluster Headache
Interventions
Civamide (Zucapsaicin)
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
26
States / cities
Phoenix, Arizona • Tucson, Arizona • Mountain View, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Sep 10, 2026, 1:44 PM EDT
Completed Phase 1 Interventional

Psilocybin for the Treatment of Cluster Headache

NCT02981173
View directory record Official record
Conditions
Cluster Headache
Interventions
0.143 mg/kg Psilocybin or 10 mg Psilocybin, 0.0143 mg/kg Psilocybin or 1 mg Psilocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 10, 2026, 1:44 PM EDT
Not yet recruiting Phase 2 Interventional

Zavegepant Intranasal Spray for the Acute Treatment of Episodic Cluster Headache

NCT07714369
View directory record Official record
Conditions
Cluster Headache
Interventions
Zavegepant 20 mg
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 10, 2026, 1:44 PM EDT